Skip to content

Author

Yi-Fei Cheng

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

CD34+-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: a large cohort study focusing on haploidentical transplantation.

CD34+-selected stem cell boost is safe and highly effective for refractory PGF after allo-HSCT, including in haploidentical recipients and those who have failed TPO-RAs.

Y. He, Lin-Wei Shi, R. Ma et al. · 0 citations
Open access Oct 2026

Single-cell dissection of self-derived versus donor-derived T cell exhaustion niches in patients with acute myeloid leukemia

Summary Relapse remains the main cause of death in acute myeloid leukemia (AML), and T cell exhaustion is related to relapse in both non-allografting and allografting settings. However, differences in exhausted T cells (Tex) across different disease contexts remain incompletely understood. We performed single-cell RNA...

Chun-Zi Yu, Yu-Lun Chen, Xiao-Hui Zhang et al. · 0 citations
Review Open access Sep 2026

Age‐Stratified Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndromes: A Comprehensive Review

Myelodysplastic syndromes (MDS) are clonal disorders with high risk of progression to acute myeloid leukemia (AML). Allogeneic haematopoietic stem cell transplantation (allo‐HSCT), including haploidentical HSCT (haplo‐HSCT), is the only curative option. Age‐stratified selection of conditioning regimens based on organ r...

Ning Wu, Meng Lv, Xiao-Dong Mo et al. · 0 citations
Open access Sep 2026

Letermovir for cytomegalovirus prophylaxis after allogeneic hematopoietic stem cell transplantation in acute leukemia patients: results of the LETreal study

Objective Cytomegalovirus (CMV) infection can cause severe morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Letermovir is recommended as CMV prophylaxis for allo-HSCT recipients. This study aimed to further confirm the efficacy of letermovir prophylaxis in d...

Yi Xia, Qi Wen, Jing Liu et al. · 0 citations
Aug 2026

A novel conditioning regimen incorporating low-dose cyclophosphamide and thiotepa for haploidentical hematopoietic stem cell transplantation in pediatric patients with severe aplastic anemia at high risk of cardiotoxicity.

BACKGROUND High-dose cyclophosphamide (Cy)-related cardiotoxicity (CT) during transplant conditioning in patients with severe aplastic anemia (SAA) is a life-threatening complication. OBJECTIVE To evaluate the efficacy and safety of a modified conditioning regimen to reduce CT in pediatric SAA. METHODS We conducted...

Feng Zhang, P. Suo, Guan-Hua Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.